Press Release
<p>MICHAEL SECKLER APPOINTED NATIONAL SALES DIRECTOR FOR FERRING PHARMACEUTICALS</p>
<table class="newsroom">
<tr>
<td valign="top" width="57"><p><b>Contact:</b></p></td>
<td width="20" valign="top"></td>
<td width="304">
<p>Kelly Laban<br>
Kovak-Likly Communications<br>
(203)762-8833 x15 or KLaban@KLCpr.com</p>
</td>
</tr>
</table>
<p><br></p>
<p>Pictured: Michael D. Seckler, appointed national sales director for Ferring Pharmaceuticals </p>
<p>Suffern, NY – January 11, 2005 – Ferring Pharmaceuticals announced today the
appointment of Michael Seckler, of Warren, NJ, to national sales director.
Seckler joined the Company in February 2003 as district manager, eastern states.
In his new role, he will be responsible for successful implementation of the
sales strategy for Ferring’s product line. </p>
<p>“Seckler excelled as a district manager, leading his district to an
unprecedented performance level in the East,” said Olivier Delannoy, vice
president, sales, Ferring Pharmaceuticals. “We are confident that his dedication
and strong leadership ability will ensure success in his new position.” </p>
<p>Prior to joining Ferring, Seckler was a specialty district manager for
Pharmacia. He previously held the director of sales position at Caresoft and
spent 10 years at Schering Plough, where he held a variety of positions,
including district manager; product manager; and manager, managed care sales
training. </p>
<p><strong>About Ferring Pharmaceuticals</strong><br/>
Ferring Pharmaceuticals, part of the Ferring Group, a privately owned,
international pharmaceutical company, markets Bravelle<sup>®</sup> (urofollitropin for
injection, purified), Repronex<sup>®</sup> (menotropins for injections, USP) and Novarel™ (chorionic
gonadotropin for injection, USP) in the U.S. to infertility specialists and
their patients. </p>
<p>Ferring also offers the Q∙Cap™, the first needle-free reconstitution device, for
use with its line of fertility treatments. The Ferring Group specializes in the
research, development and commercialization of compounds in general and
pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and
infertility. For more information, call 888-337-7464 or visit www.ferringusa.com or www.ferringfertility.com. </p>
<p># # # </p>
EUFLEXXA (1% sodium hyaluronate) is used to relieve knee pain due to osteoarthritis. It is used in people who do not get enough relief from simple pain medications such as acetaminophen or from exercise and physical therapy.
Important Safety Information
You should not receive this product if you have had any previous allergic reaction to EUFLEXXA or hyaluronan products. You should not have an injection into the knee if you have a knee joint infection or if you have skin disease or infection around the injection site.
EUFLEXXA is only for injection into the knee performed by a qualified doctor. After you receive this injection you may need to avoid activities such as jogging, tennis, heavy lifting, or standing on your feet for a long time (more than one hour). The safety and effectiveness of repeat treatment cycles of EUFLEXXA have not been established. The safety and effectiveness of EUFLEXXA have not been shown in people under 18 years of age.
Side effects sometimes seen when EUFLEXXA is injected into the knee joint were pain, swelling, skin irritation, and tenderness and these were generally mild and did not last long.
Please see Full Prescribing Information.
Please see Important Information for Patients.
Patient Treatment Information
PLEASE CONSULT WITH YOUR DOCTOR, OR OTHER QUALIFIED HEALTH CARE PROFESSIONAL BEFORE USING ANY PRODUCT DISCUSSED WITHIN THIS WEB SITE.
This website is intended only for US residents.
Euflexxa® is a registered trademark of Ferring Pharmaceuticals Inc.
